SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jaybe5/15/2016 1:00:26 PM
1 Recommendation

Recommended By
mulanoon2007

   of 4474
 
Snapshot of Univ. Colo. screening protocols suggests broader use for pona...

Ongoing and pending trials noted for for Pona, Briga, and '788, however the first slide suggests all ALK/EGFR WT, Stage IV patients, without biomarkers for specific trials will see ponatinib off study. Not sure if this is ground work for a pending IST but the target population for Stage IV, all histologies, without any actionable molecular target would be over 75,000 patients WW, but likely a short duration of treatment.

ucdenver.edu
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News